AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31510897 — intervention group
Group type: COMPARATOR
Intervention: Vascular risk factors group
Number of subjects: 10
Study 31511239 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 58
Study 31511876 — intervention group
Group type: EXPERIMENTAL
Intervention: T1DM-Unaware
Number of subjects: 39
Study 31511876 — intervention group
Group type: EXPERIMENTAL
Intervention: T1DM-Aware
Number of subjects: 39
Study 31511876 — intervention group
Group type: COMPARATOR
Intervention: HC
Number of subjects: 39
Study 31511942 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Spectroscopy (EIS)
Number of subjects: 56
Study 31512728 — intervention group
Group type: EXPERIMENTAL
Intervention: iscalimab (10 mg/kg intravenously over 12 weeks)
Number of subjects: 15
Study 31513018 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (CIT) with oregovomab (anti-CA-125), gemcitabine/leucovorin/fluorouracil for 3 cycles, followed by nelfinavir (1250 mg bid for 5 weeks) and SBRT (40 Gy/5 fractions) during the third week of nelfinavir.
Number of subjects: 11
Study 31513018 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 11
Study 31513018 — intervention group
Group type: EXPERIMENTAL
Intervention: Oregovomab (2 mg) administered for 7 total doses (3 pre-SBRT, 1 between SBRT and resection, and 3 postoperatively)
Number of subjects: 11
Study 31513090 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical fitness (PF) assessed with the International Fitness Scale (IFIS)
Number of subjects: 191
Study 31513090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF), speed-agility, and flexibility
Number of subjects: 191
Study 31513090 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle strength (MS)
Number of subjects: 191
Study 31513090 — intervention group
Group type: EXPERIMENTAL
Intervention: CRF, MS, and speed-agility
Number of subjects: 191
Study 31513090 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility
Number of subjects: 191
Study 31513090 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall PF and all its components
Number of subjects: 191
Study 31513090 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall PF and MS
Number of subjects: 191
Study 31513090 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall PF
Number of subjects: 191
Study 31513265 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat (64%) high-energy (+47%) diet for 7 days
Number of subjects: 15
Study 31513270 — intervention group
Group type: EXPERIMENTAL
Intervention: C-terminal pro-endothelin-1 (CT-proET-1) levels
Number of subjects: 38
Study 31513270 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-regional pro-adrenomedullin (MR-proADM) levels
Number of subjects: 38
Study 31513270 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular (RV) reserve limitation
Number of subjects: 38
Study 31513270 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CT-proET-1 and MR-proADM levels
Number of subjects: 38
Study 31513270 — intervention group
Group type: COMPARATOR
Intervention: Control group (free of HF)
Number of subjects: 38
Study 31513353 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 44
Study 31514508 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive Sleep Apnea (OSA) treatment, specific intervention details not available
Number of subjects: 0
Study 31514524 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT <150 s
Number of subjects: 837
Study 31514524 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT between 150 and 249 s
Number of subjects: 837
Study 31514524 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT >250 s
Number of subjects: 837
Study 31514751 — intervention group
Group type: EXPERIMENTAL
Intervention: 2013 American Thoracic Society CPAP-tracking system algorithm
Number of subjects: 650
Study 31515130 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of Tacrolimus, use of anti-thymocyte globulins (ATG), higher B cell count, lower recent thymic emigrants (RTE) %
Number of subjects: 818
Study 31515130 — intervention group
Group type: EXPERIMENTAL
Intervention: B cell count
Number of subjects: 818
Study 31515130 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower RTE%
Number of subjects: 818
Study 31515130 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus sparing and B cell depletion
Number of subjects: 818
Study 31515430 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified CAMI-NSTEMI (SCAMI-NSTEMI) score
Number of subjects: 5775
Study 31515430 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAMI-NSTEMI score
Number of subjects: 5775
Study 31515828 — intervention group
Group type: EXPERIMENTAL
Intervention: GHX02 at 0, 1250, 2500, and 5000 mg/kg/day for 28 days
Number of subjects: 20
Study 31515828 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro tests for genotoxicity
Number of subjects: 20
Study 31515828 — intervention group
Group type: EXPERIMENTAL
Intervention: Other genetic toxicity studies
Number of subjects: 20
Study 31516602 — intervention group
Group type: EXPERIMENTAL
Intervention: gBRCAm OvCa
Number of subjects: 0
Study 31516602 — intervention group
Group type: COMPARATOR
Intervention: BRCA wild-type (BRCAwt) disease
Number of subjects: 0
Study 31516726 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Nutrition Comics
Number of subjects: 89
Study 31516726 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 89
Study 31516729 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational text messages
Number of subjects: 38
Study 31516729 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 38
Study 31516727 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise plus acupuncture
Number of subjects: 36
Study 31516727 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise plus manual therapy
Number of subjects: 36
Study 31516727 — intervention group
Group type: COMPARATOR
Intervention: Eccentric exercise alone
Number of subjects: 36
Study 31516734 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg/day for 4 weeks
Number of subjects: 13
Study 31517177 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched tumor and germline DNA NGS of a targeted panel of 201 genes
Number of subjects: 1000
Study 31517263 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Servo-Ventilation (ASV)
Number of subjects: 40
Study 31517263 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 40
Study 31517263 — intervention group
Group type: EXPERIMENTAL
Intervention: ASV
Number of subjects: 40
Study 31517263 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 40
Study 31518248 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Cognitive Health (VC Health) program
Number of subjects: 82
Study 31518254 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo story in paper format
Number of subjects: 126
Study 31518254 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo story in tablet format
Number of subjects: 126
Study 31518254 — intervention group
Group type: COMPARATOR
Intervention: Traditional brochure in paper format
Number of subjects: 126
Study 31518254 — intervention group
Group type: COMPARATOR
Intervention: Traditional brochure in tablet format
Number of subjects: 126
Study 31518270 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Support Aid (SSA) mobile app
Number of subjects: 48
Study 31518270 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 48
Study 31518280 — intervention group
Group type: EXPERIMENTAL
Intervention: BrainCheck Memory
Number of subjects: 583
Study 31518280 — intervention group
Group type: COMPARATOR
Intervention: Physician diagnosis
Number of subjects: 583
Study 31518281 — intervention group
Group type: EXPERIMENTAL
Intervention: Jawbone Up24 activity monitor and Apple iPad Mini with UP app
Number of subjects: 35
Study 31518302 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowering youth towards employment e-mentoring intervention (mentored group)
Number of subjects: 28
Study 31518302 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonmentored)
Number of subjects: 28
Study 31518302 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowering youth towards employment e-mentoring intervention
Number of subjects: 28
Study 31518304 — intervention group
Group type: EXPERIMENTAL
Intervention: iThermonitor device for continuous temperature monitoring over a 2-week period
Number of subjects: 25
Study 31518304 — intervention group
Group type: EXPERIMENTAL
Intervention: iThermonitor device
Number of subjects: 25
Study 31518315 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowering Youth Towards Employment intervention (e-mentoring), 12 modules over 12 weeks, led by trained mentors with physical disabilities.
Number of subjects: 13
Study 31518315 — intervention group
Group type: COMPARATOR
Intervention: Control group (not mentored).
Number of subjects: 13
Study 31518315 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (mentored).
Number of subjects: 13
Study 31518364 — intervention group
Group type: EXPERIMENTAL
Intervention: MILD COPD
Number of subjects: 514
Study 31518364 — intervention group
Group type: EXPERIMENTAL
Intervention: MILD EMPHYSEMATOUS
Number of subjects: 514
Study 31518364 — intervention group
Group type: EXPERIMENTAL
Intervention: SEVERE BRONCHITIC
Number of subjects: 514
Study 31518364 — intervention group
Group type: EXPERIMENTAL
Intervention: SEVERE EMPHYSEMATOUS
Number of subjects: 514
Study 31518364 — intervention group
Group type: EXPERIMENTAL
Intervention: SEVERE MIXED COPD
Number of subjects: 514
Study 31518417 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR imaging-derived infarct characteristics
Number of subjects: 284
Study 31518417 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-derived infarct characteristics
Number of subjects: 284
Study 31518565 — intervention group
Group type: EXPERIMENTAL
Intervention: MoCA normal group (score of 25-30)
Number of subjects: 334
Study 31518565 — intervention group
Group type: EXPERIMENTAL
Intervention: MoCA mildly impaired group (score of 20-24)
Number of subjects: 334
Study 31518565 — intervention group
Group type: EXPERIMENTAL
Intervention: MoCA moderately impaired group (score less than 19)
Number of subjects: 334
Study 31519154 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic, biomarker, and clinical predictors
Number of subjects: 450
Study 31519154 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic predictors and biomarkers
Number of subjects: 450
Study 31519188 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of pathogens in nasopharyngeal aspirate (NPA) specimens for asthma exacerbation patients.
Number of subjects: 602
Study 31519188 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of pathogens in nasopharyngeal aspirate (NPA) specimens for AECOPD patients.
Number of subjects: 602
Study 31519188 — intervention group
Group type: EXPERIMENTAL
Intervention: Human rhinovirus (HRV) typing (HRV-A and HRV-C).
Number of subjects: 602
Study 31519188 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A virus identification.
Number of subjects: 602
Study 31519196 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chest CT (LDCT) and circulating tumor cells (CTC) search on a blood sample, followed by two additional screening rounds at one-year intervals.
Number of subjects: 300
Study 31519196 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative LDCT and presence of CTC.
Number of subjects: 300
Study 31519196 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological impact of the screening strategy.
Number of subjects: 300
Study 31519223 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-genetic factors (demographic, clinical, and environmental)
Number of subjects: 1000
Study 31519223 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-genetic factors
Number of subjects: 1000
Study 31519223 — intervention group
Group type: EXPERIMENTAL
Intervention: Host genetics
Number of subjects: 1000
Study 31519223 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously reported associations between human genetic variants and specific taxa
Number of subjects: 1000
Study 31519676 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based exercise (minimum of 60 min of mild-to-moderate intensity full body exercise twice weekly for a 12-week period)
Number of subjects: 2500
Study 31519676 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based exercise
Number of subjects: 2500
Study 31519694 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-derived risk score (random survival forest model)
Number of subjects: 8756
Study 31519694 — intervention group
Group type: COMPARATOR
Intervention: Cox-based method
Number of subjects: 8756
Study 31519778 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT) with current stentriever/aspiration devices
Number of subjects: 496
Study 31519778 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 496
Study 31519778 — intervention group
Group type: EXPERIMENTAL
Intervention: High WMH burden
Number of subjects: 496
Study 31519778 — intervention group
Group type: EXPERIMENTAL
Intervention: High WMH quartile
Number of subjects: 496
Study 31520247 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-initiated PRO-based follow-up (open access telePRO)
Number of subjects: 593
Study 31520247 — intervention group
Group type: COMPARATOR
Intervention: Fixed-interval PRO-based follow-up (standard telePRO)
Number of subjects: 593
Study 31520402 — intervention group
Group type: EXPERIMENTAL
Intervention: IOTA simple rules
Number of subjects: 396
Study 31520402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern recognition
Number of subjects: 396
Study 31520429 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth family-focused melanoma preventive intervention
Number of subjects: 21
Study 31520559 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (4 mg/kg) plus FOLFIRI every 2 weeks
Number of subjects: 62
Study 31520559 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of eight potential biomarkers
Number of subjects: 62
Study 31520559 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-dose 3 levels of biomarkers
Number of subjects: 62
Study 31520559 — intervention group
Group type: EXPERIMENTAL
Intervention: Preliminary data
Number of subjects: 62
Study 31521016 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Kidney Injury (AKI)
Number of subjects: 583
Study 31521016 — intervention group
Group type: COMPARATOR
Intervention: No Acute Kidney Injury (non-AKI)
Number of subjects: 583
Study 31521016 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI
Number of subjects: 583
Study 31521128 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8+ TIL-positive cases (n=205, 51.1%)
Number of subjects: 401
Study 31521128 — intervention group
Group type: COMPARATOR
Intervention: CD68+ TAM-positive cases (n=184, 45.9%)
Number of subjects: 401
Study 31521128 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive CD8+ TIL and negative CD68+ TAM status
Number of subjects: 401
Study 31521128 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (PAC)
Number of subjects: 401
Study 31521128 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) analysis
Number of subjects: 401
Study 31521134 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cycles of FOLFIRINOX neoadjuvant chemotherapy followed by a short-course of carbon ion radiotherapy (CIRT)
Number of subjects: 0
Study 31521574 — intervention group
Group type: EXPERIMENTAL
Intervention: CAVI
Number of subjects: 501
Study 31521574 — intervention group
Group type: EXPERIMENTAL
Intervention: BA-PWV
Number of subjects: 501
Study 31521574 — intervention group
Group type: EXPERIMENTAL
Intervention: CF-PWV
Number of subjects: 501
Study 31521574 — intervention group
Group type: EXPERIMENTAL
Intervention: Central augmentation index
Number of subjects: 501
Study 31521672 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller cardiac ventricular size in patients with severe asthma
Number of subjects: 233
Study 31521672 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma exacerbation rate
Number of subjects: 233
Study 31522581 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum amyloid A (mSAA) levels in women with PTB
Number of subjects: 58
Study 31522581 — intervention group
Group type: COMPARATOR
Intervention: Maternal serum amyloid A (mSAA) levels in women who delivered at term (control group)
Number of subjects: 58
Study 31522581 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal outcomes (not specified)
Number of subjects: 58
Study 31522591 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting in women
Number of subjects: 932
Study 31522619 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-office blood pressure (BP) measurement
Number of subjects: 1262
Study 31522619 — intervention group
Group type: COMPARATOR
Intervention: Clinic blood pressure (BP) measurement
Number of subjects: 1262
Study 31522983 — intervention group
Group type: EXPERIMENTAL
Intervention: T2FS-based radiomic model
Number of subjects: 122
Study 31522983 — intervention group
Group type: EXPERIMENTAL
Intervention: T1FSGd-based radiomic model
Number of subjects: 122
Study 31522983 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiomic model
Number of subjects: 122
Study 31522983 — intervention group
Group type: EXPERIMENTAL
Intervention: T2FS radiomic model combined into a nomogram with clinical staging
Number of subjects: 122
Study 31522983 — intervention group
Group type: EXPERIMENTAL
Intervention: T1FSGd-based features
Number of subjects: 122
Study 31523049 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-to-target low disease activity (T2T-LDA; 44-joint count Disease Activity Score ≤ 2.4)
Number of subjects: 571
Study 31523049 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline features influencing adherence
Number of subjects: 571
Study 31523049 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticitrullinated protein antibody/rheumatoid factor positivity
Number of subjects: 571
Study 31523058 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 500 mg once daily
Number of subjects: 40
Study 31523279 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (clarithromycin, metronidazole, levofloxacin)
Number of subjects: 200
Study 31523279 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth quadruple therapy
Number of subjects: 200
Study 31523279 — intervention group
Group type: EXPERIMENTAL
Intervention: Susceptibility-guided therapy
Number of subjects: 200
Study 31523279 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical amoxicillin-containing bismuth quadruple therapy
Number of subjects: 200
Study 31523745 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31524342 — intervention group
Group type: EXPERIMENTAL
Intervention: ATX-101 (deoxycholic acid) 2 mg/cm2
Number of subjects: 165
Study 31525136 — intervention group
Group type: EXPERIMENTAL
Intervention: Community exercise with inspiratory muscle training
Number of subjects: 0
Study 31525136 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31525774 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cultures obtained before initiation of antimicrobial treatment
Number of subjects: 325
Study 31525774 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cultures obtained within 120 minutes after initiation of antimicrobial treatment
Number of subjects: 325
Study 31525774 — intervention group
Group type: EXPERIMENTAL
Intervention: Other microbiological cultures
Number of subjects: 325
Study 31526121 — intervention group
Group type: EXPERIMENTAL
Intervention: NMDAR1-abs seropositivity (IgM, IgA, and IgG)
Number of subjects: 583
Study 31526121 — intervention group
Group type: EXPERIMENTAL
Intervention: High titers of NMDAR1-abs (≥1:320)
Number of subjects: 583
Study 31526121 — intervention group
Group type: EXPERIMENTAL
Intervention: NMDAR1-abs seropositivity
Number of subjects: 583
Study 31526253 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial function assessed with MRI-FT
Number of subjects: 1235
Study 31526253 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-FT
Number of subjects: 1235
Study 31526672 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine SBRT
Number of subjects: 56
Study 31526695 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete mesocolic excision
Number of subjects: 1069
Study 31526695 — intervention group
Group type: COMPARATOR
Intervention: Conventional resections with unstandardised and limited lymph node dissection (control group)
Number of subjects: 1069
Study 31526754 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Room (ER) stratum
Number of subjects: 4509
Study 31526754 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission stratum
Number of subjects: 4509
Study 31526754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Care Unit (ICU) stratum
Number of subjects: 4509
Study 31526754 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU stratum (moderate-to-severe TBI)
Number of subjects: 4509
Study 31527168 — intervention group
Group type: EXPERIMENTAL
Intervention: INCB054329 (monotherapy)
Number of subjects: 203
Study 31527168 — intervention group
Group type: EXPERIMENTAL
Intervention: INCB057643 (monotherapy or in combination with standard-of-care)
Number of subjects: 203
Study 31527168 — intervention group
Group type: COMPARATOR
Intervention: INCB054329
Number of subjects: 203
Study 31527168 — intervention group
Group type: COMPARATOR
Intervention: INCB057643
Number of subjects: 203
Study 31527689 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma EBV DNA-negative patients (0-20 copies/ml)
Number of subjects: 518
Study 31527689 — intervention group
Group type: COMPARATOR
Intervention: Plasma EBV DNA-positive patients (>20 copies/ml)
Number of subjects: 518
Study 31527875 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment (ART)
Number of subjects: 873
Study 31527875 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment (ART) interruption
Number of subjects: 873
Study 31527875 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 13 years and older
Number of subjects: 873
Study 31527875 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunted children (height-for-age Z-scores <-2 SD)
Number of subjects: 873